The Clinical Efficacy Of Conbercept In The Treatment Of Macular Edema Secondary To Retinal Vein Occlusion And Factors Affecting The Visual Prognosis

Objective:To observe the clinical efficacy of conbercept in the treatment of macular edema secondary to nonischemic retinal vein occlusion（RVO-ME）,and to investigate the factors affecting the visual prognosis.Methods:A retrospective study was conducted on the clinical data of 43 eyes from 43 patients diagnosed with nonischemic RVO-ME from November 2020 to November 2021 in Jining First People’s Hospital.All patients were treated with the（3+PRN）regimen by intravitreal injection of conbercept.The follow-up time was at least 6 months.Patients with terminal Best corrected visual acuity（BCVA）≥0.5 were included in the good vision group,and patients with terminal BCVA<0.5 were included in the poor vision group.Indicators of the two groups at before treatment,1mo,3mo and 6mo after treatment were collected.The clinical efficacy was analyzed according to the changes of BCVA and central retinal thickness（CMT）before and after treatment.The influencing factors of visual acuity prognosis were discussed.Results:1.Analysis of basic clinical data:there was no statistically significant difference in age,gender,times of drug injection,history of hypertension,history of coronary heart disease and history of diabetes between the two groups（P>0.05）.2.Efficacy analysis:Compared with before treatment,the postoperative BCVA was significantly increased at 1mo,3mo and 6mo,and the difference was statistically significant between the two groups（P=0.000）.The difference in BCVA measured at before treatment,1mo,3mo and 6mo was statistically significant between the two groups(F _time=50.973,P=0.000).Compared with before treatment,the postoperative CMT was significantly decreased at 1mo,3mo and 6mo,and the difference was statistically significant between the two groups（P=0.000）.The difference in CMT measured at before treatment,1mo,3mo and 6mo was statistically significant between the two groups(F _time=95.739,P=0.000).3.External limiting membrane（ELM）continuity and Ellipsoid zone（EZ）integrity analysis:there were 19 and 11 patients with ELM continuity and EZ integrity in the good vision group,and 3 and 1 patients in the poor vision group,respectively.The results revealed the ELM integrity,and EZ integrity of the good vision group were significantly better than those of the poor vision group（P=0.000,0.002）.4.Analysis of influencing factors for vision prognosis:Univariate binary logistic regression analysis showed that baseline BCVA,CMT,ELM continuity,EZ integrity were correlated with vision prognosis（P=0.001,0.017,0.000,0.007）.Multivariate binary logistic regression analysis showed that baseline BCVA,ELM continuity,EM integrity were significantly correlated with vision outcome（P=0.010,0.008,0.018）,while baseline CMT was not correlated with vision outcome（P=0.152）.Conclusion:1.Intravitreal injection of conbercept can effectively improve visual acuity and reduce central retinal thickness of nonischemic RVO-ME patients in the short term.2.Baseline BCVA,ELM continuity and EZ integrity were the influencing factors for the prognosis of visual acuity,and could be used as indicators to evaluate the prognosis of visual acuity of RVO-ME.2.Baseline CMT was not the influencing factors for the prognosis of visual acuity of RVO-ME.